comparemela.com

Latest Breaking News On - Collaborative connector - Page 1 : comparemela.com

Molecule holds promise to reprogram white blood cells for better cancer treatment

 E-Mail IMAGE: Pictured L-R: Caitlin Brandle, research assistant, Dr. Gang Zhou, Timothy Kim, undergraduate student, Nada S. Aboelella, PhD, graduate student, Dr. Zhi-Chun Ding, assistant professor view more  Credit: Kim Ratliff, AU photographer Cancer immunotherapy using designer immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient s blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells. Then these genetically modified CAR T cells are expanded to large quantity and infused back to the patient.

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity

Study shows how STAT5 optimizes function of CD4+ T cells to drive antitumor immunity Cancer immunotherapy using designer immune cells has revolutionized cancer treatment in recent years. In this type of therapy, T cells, a type of white blood cell, are collected from a patient s blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) that is designed to enable T cells to recognize and destroy cancer cells. Then these genetically modified CAR T cells are expanded to large quantities and infused back to the patient. CAR T cell-based immunotherapies have seen remarkable outcomes in some patients with certain types of cancer, but more work is needed to improve the persistence and function of CAR T cells so that more patients can benefit from this type of therapy.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.